BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3037 related articles for article (PubMed ID: 7665221)

  • 21. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
    Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
    Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
    Pavone L; Andrulli S; Santi R; Majori M; Buzio C
    Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
    Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
    J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.
    Mertens WC; Banerjee D; al-Mutter N; Stitt L; Bramwell VH; Lala PK
    Cancer Immunol Immunother; 1995 Nov; 41(5):271-9. PubMed ID: 8536272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM; Zhu HG; Anderer FA
    Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.
    Ishihara S; Nieda M; Kitayama J; Osada T; Yabe T; Kikuchi A; Koezuka Y; Porcelli SA; Tadokoro K; Nagawa H; Juji T
    J Immunol; 2000 Aug; 165(3):1659-64. PubMed ID: 10903777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of large and small CD3- CD56+ lymphocytes mediating NK-associated activities.
    Ortaldo JR; Winkler-Pickett R; Kopp W; Kawasaki A; Nagashima K; Okumura K; Yagita H; Bach FH
    J Leukoc Biol; 1992 Sep; 52(3):287-95. PubMed ID: 1381742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes.
    Poggi A; Tomasello E; Revello V; Nanni L; Costa P; Moretta L
    Int Immunol; 1997 Sep; 9(9):1271-9. PubMed ID: 9310830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells.
    Maeda M; Shadeo A; MacFadyen AM; Takei F
    J Immunol; 2004 May; 172(10):6115-22. PubMed ID: 15128797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
    Frederiksen KS; Lundsgaard D; Freeman JA; Hughes SD; Holm TL; Skrumsager BK; Petri A; Hansen LT; McArthur GA; Davis ID; Skak K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1439-49. PubMed ID: 18286285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of CD56+ NK T and gamma delta T cells from cord blood of human neonates.
    Musha N; Yoshida Y; Sugahara S; Yamagiwa S; Koya T; Watanabe H; Hatakeyama K; Abo T
    Clin Exp Immunol; 1998 Aug; 113(2):220-8. PubMed ID: 9717971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
    Biron CA; Young HA; Kasaian MT
    J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower concentrations of methyl-β-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood.
    Lü HZ; Zhu AY; Chen Y; Tang J; Li BQ
    Hum Immunol; 2011 Jul; 72(7):538-46. PubMed ID: 21540068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 152.